Sort by
Refine Your Search
-
Postdoctoral Research Fellow to work on the design, development, and realization of future communications technologies. You will be part of the team and contribute to ongoing developments in theory, algorithms
-
suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers
-
algorithms. The candidate should have the following skills: • Strong technical, analytical, and quantitative abilities; • Strong interpersonal, organizational, and communication skills, and the willingness
-
use of data and algorithms. Excellent written and verbal communication skills and ability to communicate effectively with a variety of different stakeholders, e.g., academics, business executives
-
to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific
-
approach to treating diseases at their genetic source by 'interfering' with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn
-
, spanning a range of disease indications. Guided by this full-spectrum approach, we are committed to making CRISPR-based medicines a reality for people suffering from genetic diseases and to creating novel
-
-spectrum approach, we are committed to making CRISPR-based medicines a reality for people suffering from genetic diseases and to creating novel engineered cell therapies for various rare diseases
-
at Takeda provides medical support across the asset lifecycle, from early clinical development to marketed products, in three areas, Gastrointestinal and Inflammation, Neuroscience, and Rare Genetics
-
prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA